Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | PTPRC | P08575 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbamic Acid SCHEMBL2847020 | 0.84 | CYP3A4 (0.38) | TSHRCYP1A2CYP3A4 | |
| SCHEMBL10573107 | 0.78 | HSP90AA1 (0.33) | HSP90AA1 | |
| SCHEMBL12873561 | 0.74 | TSHR (0.34) | HDAC8HSP90AA1HTTTSHR | |
| SCHEMBL11571395 | 0.74 | ESR1 (0.32) | — | |
| SCHEMBL1225311 | 0.72 | CYP2D6 (0.47) | TSHRCYP1A2 | |
| SCHEMBL20515576 | 0.72 | HSP90AA1 (0.35) | HSP90AA1 | |
| SCHEMBL32679727 | 0.71 | LMNA (0.39) | CYP1A2GAA | |
| SCHEMBL12873564 | 0.69 | TAAR1 (0.36) | TSHR | |
| SCHEMBL10519597 | 0.68 | TRPM8 (0.36) | — | |
| SCHEMBL9736537 | 0.68 | SMN1; SMN2 (0.41) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9162988-B2 | Therapeutic or prophylactic agent for allergic dermatitis | TORAY INDUSTRIES, INC. (JP) | 2015-10-20 | — | — | US | disclosed |
| US-20130150390-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | TORAY INDUSTRIES, INC. (JP) | 2013-06-13 | — | — | US | disclosed |
| US-8269009-B2 | Methods and compositions for treating liquid tumors | ELAN PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-7893046-B2 | agent comprises as an effective ingredient a glycine derivative or a pharmaceutically acceptable salt thereof, for example [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid] | TORAY INDUSTRIES, INC. (JP) | 2011-02-22 | — | — | US | disclosed |
| US-7879837-B2 | administering glycine derivatives such as (E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid, used for the treatment of nervous system disorders | TORAY INDUSTRIES, INC. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-7820687-B2 | Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-2231185-A1 | METHODS AND COMPOSITIONS FOR TREATING LIQUID TUMORS | Elan Pharmaceuticals Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20100016345-A1 | PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. | 2010-01-21 | — | — | US | disclosed |
| US-20090312353-A1 | Methods and compositions for treating liquid tumors | ELAN PHARMACEUTICALS, INC. | 2009-12-17 | — | — | US | disclosed |
| US-20090275599-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR MULTIPLE SCLEROSIS | TORAY INDUSTRIES, INC. (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20090253724-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR LEUKEMIA | TORAY INDUSTRIES, INC. (JP) | 2009-10-08 | — | — | US | disclosed |
| US-7579466-B2 | Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7566724-B2 | Glycine derivative and use thereof | TORAY INDUSTRIES, INC. (JP) | 2009-07-28 | — | — | US | disclosed |
| WO-2009075806-A1 | METHODS AND COMPOSITIONS FOR TREATING LIQUID TUMORS | ELAN PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090093508-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | TORAY INDUSTRIES, INC. (JP) | 2009-04-09 | — | — | US | disclosed |
| EP-1996559-A1 | PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20080085910-A1 | Glycine Derivative and Use Thereof | TORAY INDUSTRIES, INC. (JP) | 2008-04-10 | — | — | US | disclosed |
| US-20080058357-A1 | PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. | 2008-03-06 | — | — | US | disclosed |
| WO-2007101165-A1 | PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016345-A1 | PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | VCAM1, ICAM1, CD4 | HDAC8 3179/4885HSP90AA1 2566/4885HTT 3277/4885 |
| US-20090093508-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | HRH2, TSLP, ENPEP | HDAC8 2532/4885HSP90AA1 1606/4885HTT 3376/4885 |
| US-20130150390-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | HRH2, TSLP, ENPEP | HDAC8 2532/4885HSP90AA1 1606/4885HTT 3376/4885 |
| US-20080085910-A1 | Glycine Derivative and Use Thereof | GNMT, SI, SLC7A11 | HDAC8 4345/4885HSP90AA1 2523/4885HTT 2669/4885 |
| US-20090275599-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR MULTIPLE SCLEROSIS | PMP22, MGMT, ENPEP | HDAC8 1567/4885HSP90AA1 2780/4885HTT 1427/4885 |
| US-20090253724-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR LEUKEMIA | MCL1, ENPEP, SLC7A1 | HDAC8 2752/4885HSP90AA1 2582/4885HTT 2514/4885 |
| US-20090312353-A1 | Methods and compositions for treating liquid tumors | ITGB4, ITGA4, ITGB3 | HDAC8 1104/4885HSP90AA1 759/4885HTT 4877/4885 |
| US-20080058357-A1 | PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | VCAM1, ICAM1, CD4 | HDAC8 3179/4885HSP90AA1 2566/4885HTT 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.